FDA Clears First-in-Class Vectorized Antibody Trial for ALS Targeting TDP-43 Pathology
核心洞察
VectorY Therapeutics (搜索) received FDA clearance for a Phase 1/2 trial of VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology that drives up to 97% of ALS (搜索) cases.
The PIONEER-ALS (搜索) trial will evaluate safety and tolerability of VTx-002 delivered via AAV vector in 12 adults with ALS, using a single intracisterna magna administration.
VTx-002 is designed to selectively target toxic TDP-43 species while avoiding properly folded forms, potentially addressing the majority of ALS (搜索) patients unlike current mutation-specific therapies.
Dutch biotech VectorY Therapeutics (搜索) has received FDA clearance to proceed with a Phase 1/2 trial of VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (搜索) (ALS (搜索)). The development marks a significant milestone in addressing a therapeutic target implicated in up to 97% of ALS cases.
Novel Vectorized Antibody Approach
VTx-002 represents a breakthrough in targeting intracellular proteins through VectorY's proprietary vectorized antibody platform. The therapy delivers an engineered antibody designed to selectively target toxic species of TAR DNA-binding protein 43 (搜索) (TDP-43), a protein involved in DNA repair that has emerged as a possible driver of nerve damage in ALS (搜索).
The antibody is delivered via an adeno-associated virus (AAV5.2) vector and produced continuously within target cells following a single intracisterna magna (ICM) administration. By binding only to pathological forms of TDP-43, the therapeutic aims to reduce protein aggregation, correct mis-splicing abnormalities, and restore normal nuclear function while minimizing side effects by avoiding properly folded forms.
PIONEER-ALS Trial Design
The PIONEER-ALS (搜索) Phase 1/2 trial will be conducted as an open-label, dose-escalation study evaluating two dose levels of VTx-002 in 12 adults with ALS. The primary objective focuses on evaluating safety and tolerability of the vectorized antibody approach.
Secondary and exploratory endpoints include assessment of neurofilament light chain (NfL), a widely used surrogate marker for neuronal damage in ALS (搜索), and novel TDP-43 pathway-related biomarker trajectories. Clinical endpoints will encompass ALSFRS-R scores, slow-vital capacity, hand-held dynamometry, and survival measures.
Addressing Critical Unmet Need
ALS (搜索) represents a universally fatal neurodegenerative disease with no cure and limited symptomatic treatment options. In the United States, more than 5,000 new cases are diagnosed annually, with over 30,000 people currently living with the disease. Median survival ranges from 2-3 years after diagnosis, and someone is either diagnosed with or dies from ALS every 90 minutes.
Current therapies have demonstrated limited efficacy in slowing ALS (搜索) progression. Existing treatments like Biogen's Qalsody (tofersen) are restricted to patients with specific mutations, while VTx-002 is not expected to be suitable for ALS patients with SOD1 (搜索) genetic mutations or cases linked to FUS (搜索) mutations.
Clinical Development Leadership
VectorY is collaborating with James Berry, MD, PhD, chief of the Division of Motor Neuron Diseases and director of the Neurological Clinical Research Institute (NCRI) at Mass General Brigham (搜索), who serves as the PIONEER-ALS (搜索) Global Coordinating Investigator.
"The FDA's clearance to proceed with our Phase 1/2 study marks a pivotal milestone for VectorY, as we strive to transform the neurodegenerative disease landscape with our novel vectorized antibodies that are specifically designed to address the well-established biology driving disease manifestations," said Jim Scibetta, VectorY's chief executive officer.
The Amsterdam-headquartered company raised $138 million in a Series A round two years ago, co-led by EQT Life Sciences (搜索) and Forbion (搜索), representing one of the largest European biotech financings of 2023.